KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Common Equity (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Common Equity for 11 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 2.34% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 2.34% year-over-year, with the annual reading at $1.1 billion for FY2025, 2.34% down from the prior year.
  • Common Equity hit $1.1 billion in Q4 2025 for Fulgent Genetics, down from $1.1 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.3 billion in Q1 2022 to a low of $801.6 million in Q1 2021.
  • Historically, Common Equity has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2023.
  • Biggest five-year swings in Common Equity: soared 957.78% in 2021 and later fell 11.21% in 2024.
  • Year by year, Common Equity stood at $1.2 billion in 2021, then rose by 8.92% to $1.3 billion in 2022, then dropped by 10.76% to $1.1 billion in 2023, then fell by 0.01% to $1.1 billion in 2024, then decreased by 2.34% to $1.1 billion in 2025.
  • Business Quant data shows Common Equity for FLGT at $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.